Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Completed · Phase 3
Conditions studied: Glabellar Frown Lines, Canthal Lines
In brief
This study to assess aesthetic improvement following treatment with QM1114-DP.
Key facts
- Study ID
- NCT05148000
- Run by
- Galderma R&D
- People needed
- 25
- Starts
- 2023-01-23
- Expected to finish
- 2023-06-23
- Last updated by the study team
- 2026-05-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Male or Female 18 years or older
- Moderate to severe bilaterally symmetrical LCL as assessed by the investigator
- Moderate to severe GL at maximum frown as assessed by the Investigator
You may not qualify if…
- Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment
- Female who was pregnant, breast feeding or intended to conceive a child during the study.
- Known allergy to hypersensitivity or any component of the Investigational product
Where it is running
- Galderma Research Site — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.